InsiderSignal.AI

InsiderSignal.ai

TLPH - Talphera, Inc.

Insider Purchase by Angotti Vincent J. (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Angotti Vincent J., serving as CEO at Talphera, Inc. (TLPH), purchased 105,364 shares at $0.81 per share, for a total transaction value of $85,587.00. Following this transaction, Angotti Vincent J. now holds 577,395 shares of TLPH.

This purchase represents a 22.00% increase in Angotti Vincent J.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, February 12, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 8 days after the trade was made.

Talphera, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Angotti Vincent J.

CEO

Vincent J. Angotti is the Chief Executive Officer and a director of Talphera, Inc. (TLPH), positions he has held since March 2017.[[1]](https://talphera.com/team/vincent-j-angotti/)[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti)[[3]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlph/talphera/management) Aged 57, he brings over two decades of experience leading executive and commercial teams in public and private life sciences companies.[[1]](https://talphera.com/team/vincent-j-angotti/)[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti) Prior to Talphera (formerly AcelRx Pharmaceuticals), he served as CEO of XenoPort, Inc., where he orchestrated the acquisition of Horizant from GSK, executed a successful rebranding and relaunch, culminating in XenoPort's $0.5 billion acquisition by Arbor Pharmaceuticals in 2016.[[1]](https://talphera.com/team/vincent-j-angotti/) Angotti holds a B.S. in Business Management from Cornell University and an MBA with honors from Columbia University.[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti) He owns approximately 0.79% of Talphera's shares, valued at around $321,000, and his total compensation is about $1.04 million annually, comprising 64% salary and 36% bonuses/stock/options.[[2]](https://fintool.com/app/research/companies/TLPH/people/vincent-angotti)[[3]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlph/talphera/management) Recently, on February 12, 2026, he purchased 105,364 shares at $0.8123 each, along with 594,000 stock options, demonstrating confidence in the company amid its development-stage focus on products like Niyad for CRRT anticoagulation.[[4]](https://www.gurufocus.com/insider/29206/vincent-j.-angotti)[[5]](https://www.stocktitan.net/sec-filings/TLPH/form-4-talphera-inc-insider-trading-activity-519d79c3f983.html)[[6]](https://www.investing.com/news/insider-trading-news/talphera-tlph-ceo-angotti-buys-85k-in-shares-93CH-4517420)

View full insider profile →

Trade Price

$0.81

Quantity

105,364

Total Value

$85,587.00

Shares Owned

577,395

Trade Date

Thursday, February 12, 2026

9 days ago

SEC Filing Date

Friday, February 20, 2026

Filed 8 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Talphera, Inc.

Company Overview

No company information available
View news mentioning TLPH

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4158051

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime